Skip to content

Clinical Study of Yiqi Tongluo Prescription on Interventional Restenosis of Ischemic Cerebrovascular Disease

Clinical Study of Yiqi Tongluo Prescription on Interventional Restenosis of Ischemic Cerebrovascular Disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037984
Enrollment
Unknown
Registered
2020-09-08
Start date
2020-09-11
Completion date
Unknown
Last updated
2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Cerebrovascular Disease

Interventions

Sponsors

Dongfang Hospital of Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with ischemic cerebrovascular disease were diagnosed by imaging examination; 2. Patients aged 35-80 years old; 3. Patients with endovascular interventional therapy; 4. Patients with Qi deficiency, blood stasis and phlegm obstruction were diagnosed by TCM syndrome score scale; 5. Patients with 0-2 scores of modified Rankin scale before onset of disease; 6. Patients who voluntarily participated in the study and have signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who are expected to survive for less than 2 years; 2. Patients with severe systemic diseases or unsuitable / intolerant dual antiplatelet therapy; 3. Patients with severe neurological dysfunction (MRS score >= 3) before the stroke or TIA attack; 4. Patients with severe myocardial infarction within 2 weeks; 5. Patients with moyamoya disease, active arteritis and unexplained non atherosclerotic stenosis; 6. Patients with international normalized ratio (INR) > 1.5; 7. Pregnant women; 8. Patients who are not suitable for endovascular therapy as judged by neurologists and Neurointerventional physicians. 9. Patients with severe heart, liver and kidney damage; 10. Patients with a history of mental illness and mental retardation.

Design outcomes

Primary

MeasureTime frame
Degree of arterial stenosis;

Secondary

MeasureTime frame
FABP4;NIHSS, mRS, BI;Adverse events;

Countries

China

Contacts

Public ContactWangge Sheng

Dongfang Hospital of Beijing University of Chinese Medicine

wanggesh@sina.com+86 10-67689735

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026